Cytogen shuts down Cellcor division

Article

After months of unsuccessful searching for a buyout candidate for its Cellcor subsidiary, Cytogen closed the division on Sept. 18. Cytogen bought Cellcor in 1995 in hopes of bringing to market that company’s autolymphocyte therapy (ALT) cancer

After months of unsuccessful searching for a buyout candidate for its Cellcor subsidiary, Cytogen closed the division on Sept. 18. Cytogen bought Cellcor in 1995 in hopes of bringing to market that company’s autolymphocyte therapy (ALT) cancer therapy technology in development. That effort apparently didn’t go as planned, however, and Cytogen early this spring put Cellcor on the block. Cytogen reported in July that unless the company was able to find a buyer by September, Cellcor’s operations would cease.

Shutting Cellcor down is part of the Princeton, NJ, company’s attempt to reduce operating expenses and focus its corporate efforts on marketing radiopharmaceutical agents OncoScint, ProstaScint, and Quadramet. Cytogen tightened its belt further last month when it sold its interest in its subsidiary Targon back to the original owner, pharmaceutical firm Elan of Dublin, Ireland, after only two years of ownership. In addition to closing Cellcor and divesting its Targon interest, Cytogen expects to cut its workforce by 30%, according to Joseph Reiser, president and CEO. Cytogen anticipates a special charge in the third quarter of 1998 for severance and other closure-related expenses.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.